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Background: To date, evaluation of the association of the ABO blood group and breast cancer has yielded mixed
results. SNP rs505922, located within the first intron of the ABO gene, has been associated with the
adenocarcinoma subtype of pancreatic cancer. To evaluate the association between genetic variation in the ABO
blood group and risk of breast cancer, rs505922 was genotyped in 629 Caucasian women with invasive breast
cancer, representing a variety of clinical and pathological tumor types.
Methods: Genomic DNA was isolated from blood. TaqMan SNP assay C_2253769_10 was used to determine
genotypes for each patient at rs505922. Statistical analysis was performed using chi-square analysis using a P-value
<0.05 to define significance.
Results: Genotypes were generated for 100% of the 629 patients in this study. Allele and genotype frequencies did
not vary significantly for age at diagnosis, tumor stage, size or grade, hormone, HER2 or lymph node status, intrinsic
subtype, tumor type or patient outcome.
Conclusions: Allele frequencies for rs505922 did not differ between women with breast cancer and published
HapMap frequencies from women of European descent. Further stratification into different tumor phenotypes also
failed to reveal an association between rs505922 and any clinical characteristics. Together, these data suggest that
the minor allele of rs505922 and the resulting non-O blood types are not associated with increased risk or less
favorable tumor characteristics or prognosis in breast cancer.Background
The first association between the ABO blood group and
cancer risk was reported in 1953 in English patients with
stomach cancer, where blood group A was associated
with increased risk of stomach cancer and blood group
O conferred a protective advantage [1]. A similar associ-
ation between increased risk of gastric cancer and blood
group A was reported as recently as 2010 [2]. In oral
cancer, loss of the A and B antigens is associated with
increased cell migration, in non-small cell lung cancer,
the A blood group is associated with improved survival,
and in ovarian cancer the B antigen is associated with
increased risk [3-6].* Correspondence: r.ellsworth@wriwindber.org
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reproduction in any medium, provided the orA number of studies have investigated the role of the
ABO blood group in breast cancer risk and pathology.
Two early publications found no association between
ABO blood group and risk of breast cancer in either
English or American patient populations [6,7]. In more
recent studies, the A antigen was associated with
increased risk of developing invasive ductal carcinoma in
166 Greek women, while in a group of 565 Turkish
women, no association was seen between breast cancer
risk and any ABO blood types [8,9]. These differences in
risk assessment between cancer risk and the ABO blood
group may be attributed to differences in ABO frequen-
cies between populations, the importance of using com-
parable case and control groups, and methods for
determining ABO blood types.
In 2009, an agnostic approach to identify genes asso-
ciated with risk of developing pancreatic cancer further
supported the association between the ABO blood groupl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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polymorphisms (SNPs) in 1,896 patients with pancreatic
cancer and 1,939 controls revealed a significant associ-
ation between SNP rs505922, located within the first in-
tron of the ABO glycosyltransferase (ABO) gene [10].
The protective T allele of rs505922 is in linkage disequi-
librium with a single base pair deletion that encodes the
O antigen, suggesting that the A and B blood antigens
may be associated with higher risk of pancreatic cancer.
In a follow-up study, the role of the ABO blood group
was re-evaluated in 15,359 patients treated at the Euro-
pean Institute of Oncology with a variety of cancer types.
An association with the ABO blood group was detected
only for pancreatic cancer [11]. Importantly, the protect-
ive effect of the O allele was not associated with all types
of pancreatic cancer but was limited to the adenocarcin-
oma subtype.
To determine whether that ABO blood group is asso-
ciated with risk of breast cancer, SNP rs505922 was gen-
otyped in 629 Caucasian women with invasive breast
cancer diagnosed between 2001 and 2010. Data were
then evaluated by a number of pathological characteris-
tics including age at diagnosis, hormonal and HER2 sta-




Caucasian women with invasive breast cancer diagnosed
between 2001 and 2009 were selected from the Clinical
Breast Care Project (CBCP) database. Blood samples
were collected with approval from the Walter Reed
Army Medical Center Human Use Committee and Insti-
tutional Review Board. All subjects enrolled in the CBCP
voluntarily agreed to participate and gave written
informed consent.
Diagnosis of every specimen was performed by a sin-
gle, dedicated breast pathologist from hematoxylin and
eosin (H&E) stained slides; staging was performed using
guidelines defined by the AJCC Cancer Staging Manual
sixth edition [12] and grade assigned using the Notting-
ham Histologic Score [13,14]. ER and PR status were
determined by immunohistochemical (IHC) analysis at a
clinical laboratory (MDR Global, Windber, PA) and
HER2 status was assayed using the PathVysionW HER-2
DNA Probe kit (Abbott Laboratories, Abbott Park, IL)
according to manufacturer’s protocols.
SNP genotyping
Genomic DNA was isolated from blood clots using the
Gentra Clotspin and Puregene DNA purification kits
(Qiagen., Valencia, CA). Aliquots of DNA (10 ng) were
amplified in duplicate by PCR using the TaqMan SNP
assay C_2253769_10 (Applied Biosystems, Foster City,CA), representing SNP rs505922 and analyzed on a 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA). Genotypes (CC, CT or TT) were determined
using the ABI PRISMW 7000 Sequence Detection System
software (Applied Biosystems, Foster City, CA).
Statistical analysis
Differences in genotype or allele frequencies between
different clinicopathological characteristics were calcu-
lated using chi-square analysis using rxc Contingency
Tables (www.physics.csbsju.edu/stats/contingency_NROW_
NCOLUMN_form.html). Significance was determined using
P< 0.05.
Results
Clinicopathological characteristics of the patient
population
The average age at diagnosis for the 629 Caucasian
women with invasive breast cancer was 58.94 years
(range 28–97 years) and the majority (74%) was post-
menopausal at diagnosis. Most tumors were invasive
ductal carcinomas (IDCA) (70%), ER positive (78%),
HER2 negative (82%) and of the luminal A (ER+/HER2-)
subtype (74%). Tumors were divided between well-
differentiated (33%), moderately-differentiated (38%) and
poorly-differentiated (29%). Most tumors were early
stage with 86% being stage I-II and 67% having negative
lymph node status. Seventeen percent of the patients
had died of disease.
Frequency of rs505922 in women with invasive breast
cancer
Of the 629 samples assayed in this study, six (1%) pro-
duced discordant genotypes between duplicate samples
during the original run; these samples were run a second
time to achieve concordance among genotypes for all
duplicate samples. Allele frequencies were 0.65 for the T
allele and 0.35 for the C allele. Chi-square analysis
revealed that the genotype frequencies were in Hardy-
Weinberg Equilibrium (P= 0.961). Neither genotype nor
allele frequencies differed significantly from those
reported for Caucasians in the CSHL-HAPMAP panel
(P= 0.809 and P= 0.654, respectively).
Evaluation of rs505922 genotype and allele frequencies
with clinicopathological characteristics
Allele and genotype frequencies were compared for age
at diagnosis, tumor stage, size and grade, hormone,
HER2 and lymph node status, intrinsic subtype, tumor
type and patient status. No significant differences were
seen by genotype (Table 1) or allele (data not shown).
To determine whether the minor C allele was associated
with any variable, CC and CT genotypes were combined.
Table 1 Genotype frequencies by clinicopathological variable
N=629 CC CT TT P-value
Age P = 0.393
<40 years 4 (12%) 11 (32%) 19 (56%)
40-49 years 12 (9%) 59 (46%) 57 (45%)
≥50 years 62 (13%) 211 (45%) 194 (42%)
Tumor Stage P = 0.143
I 49 (15%) 147 (44%) 137 (41%)
II 18 (9%) 98 (48%) 87 (43%)
III 11 (15%) 28 (40%) 32 (45%)
IV 0 (0%) 5 (33%) 10 (67%)
Tumor Size P = 0.238
T1 56 (14%) 185 (45%) 171 (41%)
T2 11 (8%) 66 (45%) 69 (47%)
T3 7 (18%) 17 (45%) 14 (37%)
Grade P = 0.852
1 25 (13%) 83 (42%) 88 (45%)
2 30 (13%) 104 (46%) 95 (41%)
3 18 (10%) 77 (44%) 79 (46%)
Hormone Statusa P = 0.583
ER + PR+ 54 (14%) 165 (43%) 162 (43%)
ER + PR- 10 (11%) 46 (49%) 37 (40%)
ER-PR- 12 (10%) 57 (45%) 56 (45%)
HER2 Status P = 0.788
Positive 9 (10%) 38 (44%) 40 (46%)
Negative 60 (13%) 201 (43%) 203 (44%)
Intrinsic Subtypeb P = 0.748
Luminal A 54 (14%) 169 (44%) 165 (42%)
Luminal B 4 (8%) 21 (45%) 22 (47%)
HER2 enriched 5 (12%) 17 (43%) 18 (45%)
Triple negative 6 (8%) 32 (42%) 38 (50%)
Tumor Type P = 0.196
IDCA 41 (10%) 191 (46%) 185 (44%)
ILCA 18 (19%) 41 (44%) 35 (37%)
Mixed ILCA/IDCA 4 (13%) 12 (40%) 14 (47%)
Otherc 8 (18%) 17 (39%) 19 (43%)
Lymph Node Statusd P = 0.546
Negative 51 (12%) 181 (44%) 183 (44%)
Positive 16 (11%) 74 (48%) 62 (41%)
Patient Status P = 0.857
Disease-freee 23 (13%) 85 (49%) 66 (38%)
Recurrence 5 (13%) 19 (49%) 15 (38%)
Dead of Disease 4 (13%) 12 (39%) 15 (48%)
aOnly a single patient had confirmed ER-PR + status, thus this rare tumor type was not included in the analysis.
bIntrinsic subtypes were defined as luminal A = ER and or PR+/HER2-; luminal B = ER and or/PR+/HER2+; HER2-enriched = ER and PR-/HER2+ and triple
negative = ER, PR and HER2-.
cOther included histological types including tubular, medullary, apocrine, and mucinous carcinomas.
dPatients with isolated tumor cells (n = 33) were not included in this analysis.
eOnly patients who have been disease-free ≥5 years were included in this analysis.
Data was not available for each variable for every patient thus “N” varies by characteristic.
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differences were detected.
Discussion
The first suggestion of an association between ABO
blood group antigens and malignancy was made almost
100 years ago, yet the role of the ABO blood group in
cancer risk and prognosis remains controversial. Results
from the pancreatic genome-wide association study
(GWAS) in 2009 renewed interest in the ABO blood
group as the T allele of SNP rs505922, located within the
first intron of the ABO gene locus, was found to confer
a protective advantage against pancreatic cancer. The T
allele has been found to be in linkage disequilibrium
with the single base pair deletion responsible for the O
blood group antigen, leading the authors to suggest that
people with non-O blood groups have increased risk of
developing pancreatic cancer [10].
In addition to the association with blood group anti-
gens, variability of SNPs within the ABO genomic region
has been associated with circulating levels of tumor ne-
crosis factor alpha (TNFα), soluble intracellular adhesion
molecule-1 (sICAM-1) and alkaline phosphatase [15-17].
Because these tumor-promoting factors may also provide
an environment favoring breast tumor development,
variation of rs505922 may contribute to increased risk of
breast cancer development. Comparison of allele fre-
quencies in our cohort of 629 Caucasian women with in-
vasive breast cancer, however, did not differ significantly
from Caucasians in the HapMap project, suggesting that
the minor allele of rs505922 is not associated with
increased risk of breast malignancy.
In the follow-up paper by Iodice et al., which found no
association between ABO blood group and breast cancer
risk (P = 0.60) in 7,208 women treated at the European
Institute of Oncology (IEO), the importance of tumor
heterogeneity was highlighted [11]. While the GWAS
found an association between rs505922 and pancreatic
cancer overall, evaluation of ABO blood group antigens
with subtypes of pancreatic cancer in the IEO revealed
that non-O blood types were associated with the exo-
crine, but not the endocrine, form of pancreatic cancer.
Breast cancer is marked by tremendous heterogeneity in
terms of age at diagnosis, tumor pathology, and molecu-
lar characteristics. Thus, the ABO blood group may be
associated with increased risk or prognosis of certain
subtypes of breast cancer. Neither allele nor genotype
frequencies differed significantly by age at diagnosis,
tumor stage, grade and size, hormone, HER2 and lymph
node status, intrinsic subtype or prognosis suggesting
that the ABO blood group is not associated with either
overall risk of or certain subtypes of breast cancer. It
should be noted, however, stratification of genotyping
data into phenotypic groups did, for certain pathologicalcharacteristics, result in small sample size (e.g., when
stratified by subtype, only 4, 5 and 6 patients with the
CC genotype had luminal B, HER2-enriched and triple
negative tumors, respectively). Detection of association
between genotype and phenotype where the sample size
was small could, therefore, be masked.
Our results are in agreement with those from Iodice
et al. derived largely from an Italian patient population
as well as those from Dede et al. who found no associ-
ation in 565 Turkish women [8,11] In contrast, Stamata-
kos et al. found an association between the A antigen
and IDCA and/or poor prognosis in population of Greek
women [9]. Differences between the Greek study and
the other studies that failed to find an association may
reflect the small sample size used in the Greek study,
which was based on 166 women with breast cancer,
which is much smaller than the 565 Turkish, 629 Cauca-
sian American, or 7,208 Italian women included in the
other studies.
Although this study does not support a role for the
ABO gene in breast cancer incidence or prognosis, this
study was limited to individuals with self-reported
“white” ancestry. The frequency of the ABO blood group
varies globally, thus, differences in allele frequency of
the ABO blood group must be considered when evaluat-
ing the role of ABO in disease. For example, the A anti-
gen, which was found to be associated with increased
breast cancer risk in a Greek but not a Turkish popula-
tion, is more frequent in Greeks (0.42) than in Turks
(0.34), which may influence the association between the
A blood group and disease status, although the O group
frequency is similar between the two populations (0.40
and 0.43 in Greeks and Turks, respectively).
The variability of the minor allele frequency of SNP
rs505922 also varies between populations: in a pilot
study from the 1,000 Genomes Project [18], the fre-
quency of rs505922 was 0.32 in YRI (Sub-Saharan Af-
rica), 0.352 in CHB+ JPT (China and Japan) and 0.417 in
CEU (Caucasians from Utah). Although patients from
ten European countries and Shanghai were included in
the pancreatic GWAS study, the majority of patients
were from a number of cohort studies from the United
States. Similar results were achieved when all patients
were included in the analysis and when only those of
European ancestry were included [10]. In our study, all
samples were collected from self-described white women
living in Washington DC or rural Pennsylvania. Given
the marked admixture in the United States, these 629
women likely represent a heterogeneous mixture of
European ancestries. Thus, an association that may be
detected in the more homogeneous Greek population
may be masked by the genetic contributions from other
European cultures represented in our American patient
population.
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The minor allele frequency of SNP rs505922, which is in
linkage disequilibrium with the non-O ABO blood types,
did not differ between Caucasian American women with
breast cancer and published HapMap frequencies. Further
stratification into different tumor phenotypes also failed to
reveal an association between rs505922 and any tumor
characteristics. Together, these data suggest that unlike
pancreatic cancer, where the minor rs505922 allele was
associated with increased risk, especially of exocrine
tumors, rs505922 and the resulting non-O blood types,
are not associated with increased risk or less favorable
tumor characteristics or prognosis in breast cancer.
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